Am J Psychiatry 1991; 148:1301-1308
Copyright © 1991 by American Psychiatric Association

SPECIAL ARTICLES

Recent advances in the phencyclidine model of schizophrenia

DC Javitt and SR Zukin
Department of Psychiatry, Albert Einstein College of Medicine, Montefiore Medical Center, Bronx, N.Y.

OBJECTIVE: Phencyclidine (PCP, "angel dust") induces a psychotomimetic state that closely resembles schizophrenia. As opposed to amphetamine- induced psychosis, PCP-induced psychosis incorporates both positive (e.g., hallucinations, paranoia) and negative (e.g., emotional withdrawal, motor retardation) schizophrenic symptoms. PCP-induced psychosis also uniquely incorporates the formal thought disorder and neuropsychological deficits associated with schizophrenia. The purpose of the present paper is to review recent advances in the study of the molecular mechanisms of PCP action and to describe their implications for the understanding of schizophrenic pathophysiology. METHOD: Twenty- five papers were identified that described the clinical dose and serum and CSF levels at which PCP induces its psychotomimetic effects. The dose range of PCP-induced effects were compared to the dose range at which PCP interacts with specific molecular targets and affects neurotransmission. RESULTS: It was found that PCP-induced psychotomimetic effects are associated with submicromolar serum concentrations of PCP. At these concentrations PCP interacts selectively with a specific binding site (PCP receptor) that is associated with the N-methyl-D-aspartate (NMDA)-type excitatory amino acid receptor. Occupation of its receptor by PCP induces noncompetitive inhibition of NMDA receptor-mediated neurotransmission. Other NMDA antagonists such as the dissociative anesthetic ketamine induce PCP- like neurobehavioral effects in proportion to their potency in binding to the PCP receptor and inducing NMDA receptor inhibition. CONCLUSIONS: These findings suggest that endogenous dysfunction of NMDA receptor- mediated neurotransmission might contribute to the pathogenesis of schizophrenia. The relative implications of the PCP and amphetamine models of schizophrenia are discussed in relationship to the diagnosis and etiology of schizophrenia.

This article has been cited by other articles:

				Y. Xia, C. Z. Wang, J. Liu, N. C. Anastasio, and K. M. Johnson Lithium Protection of Phencyclidine-Induced Neurotoxicity in Developing Brain: The Role of Phosphatidylinositol-3 Kinase/Akt and Mitogen-Activated Protein Kinase Kinase/Extracellular Signal-Regulated Kinase Signaling Pathways J. Pharmacol. Exp. Ther., September 1, 2008; 326(3): 838 - 848. [Abstract] [Full Text] [PDF]

				D. Dickinson and P. D. Harvey Systemic Hypotheses for Generalized Cognitive Deficits in Schizophrenia: A New Take on An Old Problem Schizophr Bull, August 9, 2008; (2008) sbn097v1. [Abstract] [Full Text] [PDF]

				T. Dejaegere, L. Serneels, M. K. Schafer, J. Van Biervliet, K. Horre, C. Depboylu, D. Alvarez-Fischer, A. Herreman, M. Willem, C. Haass, et al. Deficiency of Aph1B/C-{gamma}-secretase disturbs Nrg1 cleavage and sensorimotor gating that can be reversed with antipsychotic treatment PNAS, July 15, 2008; 105(28): 9775 - 9780. [Abstract] [Full Text] [PDF]

				M. J. Fell, K. A. Svensson, B. G. Johnson, and D. D. Schoepp Evidence for the Role of Metabotropic Glutamate (mGlu)2 Not mGlu3 Receptors in the Preclinical Antipsychotic Pharmacology of the mGlu2/3 Receptor Agonist (-)-(1R,4S,5S,6S)-4-Amino-2-sulfonylbicyclo[3.1.0]hexane-4,6-dicarboxylic Acid (LY404039) J. Pharmacol. Exp. Ther., July 1, 2008; 326(1): 209 - 217. [Abstract] [Full Text] [PDF]

				E. Y. Yuen, Q. Jiang, P. Chen, J. Feng, and Z. Yan Activation of 5-HT2A/C Receptors Counteracts 5-HT1A Regulation of N-Methyl-D-aspartate Receptor Channels in Pyramidal Neurons of Prefrontal Cortex J. Biol. Chem., June 20, 2008; 283(25): 17194 - 17204. [Abstract] [Full Text] [PDF]

				P. Harrison, L. Lyon, L. Sartorius, P. Burnet, and T. Lane Review: The group II metabotropic glutamate receptor 3 (mGluR3, mGlu3, GRM3): expression, function and involvement in schizophrenia J Psychopharmacol, May 1, 2008; 22(3): 308 - 322. [Abstract] [PDF]

				G. E. Tsai, H.-Y. Lane, C. M. VanDenBerg, Y.-C. Liu, P. Tsai, and M. W. Jann Disposition of D-Serine in Healthy Adults J. Clin. Pharmacol., April 1, 2008; 48(4): 524 - 527. [Full Text] [PDF]

				M. A. Henson, A. C. Roberts, K. Salimi, S. Vadlamudi, R. M. Hamer, J. H. Gilmore, L. F. Jarskog, and B. D. Philpot Developmental Regulation of the NMDA Receptor Subunits, NR3A and NR1, in Human Prefrontal Cortex Cereb Cortex, February 21, 2008; (2008) bhn017v1. [Abstract] [Full Text] [PDF]

				V. Bubenikova-Valesova, A. Stuchlik, J. Svoboda, J. Bures, and K. Vales Risperidone and ritanserin but not haloperidol block effect of dizocilpine on the active allothetic place avoidance task PNAS, January 22, 2008; 105(3): 1061 - 1066. [Abstract] [Full Text] [PDF]

				A. BASKYS, I. BAYAZITOV, E. ZHU, L. FANG, and R. WANG Rab-Mediated Endocytosis: Linking Neurodegeneration, Neuroprotection, and Synaptic Plasticity? Ann. N.Y. Acad. Sci., December 1, 2007; 1122(1): 313 - 329. [Abstract] [Full Text] [PDF]

				C. Villmann and C.-M. Becker On the Hypes and Falls in Neuroprotection: Targeting the NMDA Receptor Neuroscientist, December 1, 2007; 13(6): 594 - 615. [Abstract] [PDF]

				H. Homayoun and B. Moghaddam NMDA Receptor Hypofunction Produces Opposite Effects on Prefrontal Cortex Interneurons and Pyramidal Neurons J. Neurosci., October 24, 2007; 27(43): 11496 - 11500. [Abstract] [Full Text] [PDF]

				R. W. Buchanan, D. C. Javitt, S. R. Marder, N. R. Schooler, J. M. Gold, R. P. McMahon, U. Heresco-Levy, and W. T. Carpenter The Cognitive and Negative Symptoms in Schizophrenia Trial (CONSIST): The Efficacy of Glutamatergic Agents for Negative Symptoms and Cognitive Impairments Am J Psychiatry, October 1, 2007; 164(10): 1593 - 1602. [Abstract] [Full Text] [PDF]

				L. Kargieman, N. Santana, G. Mengod, P. Celada, and F. Artigas Antipsychotic drugs reverse the disruption in prefrontal cortex function produced by NMDA receptor blockade with phencyclidine PNAS, September 11, 2007; 104(37): 14843 - 14848. [Abstract] [Full Text] [PDF]

				R. W. Buchanan, R. Freedman, D. C. Javitt, A. Abi-Dargham, and J. A. Lieberman Recent Advances in the Development of Novel Pharmacological Agents for the Treatment of Cognitive Impairments in Schizophrenia Schizophr Bull, September 1, 2007; 33(5): 1120 - 1130. [Abstract] [Full Text] [PDF]

				P.R. Corlett, G.K. Murray, G.D. Honey, M.R.F. Aitken, D.R. Shanks, T.W. Robbins, E.T. Bullmore, A. Dickinson, and P.C. Fletcher Disrupted prediction-error signal in psychosis: evidence for an associative account of delusions Brain, September 1, 2007; 130(9): 2387 - 2400. [Abstract] [Full Text] [PDF]

				S. R. Laviolette Dopamine Modulation of Emotional Processing in Cortical and Subcortical Neural Circuits: Evidence for a Final Common Pathway in Schizophrenia? Schizophr Bull, July 1, 2007; 33(4): 971 - 981. [Abstract] [Full Text] [PDF]

				A. Mouri, Y. Noda, A. Noda, T. Nakamura, T. Tokura, Y. Yura, A. Nitta, H. Furukawa, and T. Nabeshima Involvement of a Dysfunctional Dopamine-D1/N-Methyl-D-aspartate-NR1 and Ca2+/Calmodulin-Dependent Protein Kinase II Pathway in the Impairment of Latent Learning in a Model of Schizophrenia Induced by Phencyclidine Mol. Pharmacol., June 1, 2007; 71(6): 1598 - 1609. [Abstract] [Full Text] [PDF]

				E. A. Rabiner Imaging of striatal dopamine release elicited with NMDA antagonists: is there anything there to be seen? J Psychopharmacol, May 1, 2007; 21(3): 253 - 258. [Abstract] [PDF]

				P. H. Boeijinga, L. Soufflet, F. Santoro, and R. Luthringer Ketamine effects on CNS responses assessed with MEG/EEG in a passive auditory sensory-gating paradigm: an attempt for modelling some symptoms of psychosis in man J Psychopharmacol, May 1, 2007; 21(3): 321 - 337. [Abstract] [PDF]

				A. Nakajima, T. Yamakuni, K. Matsuzaki, N. Nakata, H. Onozuka, A. Yokosuka, Y. Sashida, Y. Mimaki, and Y. Ohizumi Nobiletin, a Citrus Flavonoid, Reverses Learning Impairment Associated with N-Methyl-D-aspartate Receptor Antagonism by Activation of Extracellular Signal-Regulated Kinase Signaling J. Pharmacol. Exp. Ther., May 1, 2007; 321(2): 784 - 790. [Abstract] [Full Text] [PDF]

				Z. Gu, Q. Jiang, and Z. Yan RGS4 Modulates Serotonin Signaling in Prefrontal Cortex and Links to Serotonin Dysfunction in a Rat Model of Schizophrenia Mol. Pharmacol., April 1, 2007; 71(4): 1030 - 1039. [Abstract] [Full Text] [PDF]

				Z. Abdul-Monim, J. C. Neill, and G. P. Reynolds Sub-chronic psychotomimetic phencyclidine induces deficits in reversal learning and alterations in parvalbumin-immunoreactive expression in the rat J Psychopharmacol, March 1, 2007; 21(2): 198 - 205. [Abstract] [PDF]

				P. D. Butler, A. Martinez, J. J. Foxe, D. Kim, V. Zemon, G. Silipo, J. Mahoney, M. Shpaner, M. Jalbrzikowski, and D. C. Javitt Subcortical visual dysfunction in schizophrenia drives secondary cortical impairments Brain, February 1, 2007; 130(2): 417 - 430. [Abstract] [Full Text] [PDF]

				T. NABESHIMA, A. MOURI, R. MURAI, and Y. NODA Animal Model of Schizophrenia: Dysfunction of NMDA Receptor-Signaling in Mice following Withdrawal from Repeated Administration of Phencyclidine Ann. N.Y. Acad. Sci., November 1, 2006; 1086(1): 160 - 168. [Abstract] [Full Text] [PDF]

				E. Pomarol-Clotet, G. D. Honey, G. K. Murray, P. R. Corlett, A. R. Absalom, M. Lee, P. J. McKenna, E. T. Bullmore, and P. C. Fletcher Psychological effects of ketamine in healthy volunteers: Phenomenological study The British Journal of Psychiatry, August 1, 2006; 189(2): 173 - 179. [Abstract] [Full Text] [PDF]

				J. W. Kinney, C. N. Davis, I. Tabarean, B. Conti, T. Bartfai, and M. M. Behrens A Specific Role for NR2A-Containing NMDA Receptors in the Maintenance of Parvalbumin and GAD67 Immunoreactivity in Cultured Interneurons J. Neurosci., February 1, 2006; 26(5): 1604 - 1615. [Abstract] [Full Text] [PDF]

				R. Narendran, W. G. Frankle, R. Keefe, R. Gil, D. Martinez, M. Slifstein, L. S. Kegeles, P. S. Talbot, Y. Huang, D.-R. Hwang, et al. Altered Prefrontal Dopaminergic Function in Chronic Recreational Ketamine Users Am J Psychiatry, December 1, 2005; 162(12): 2352 - 2359. [Abstract] [Full Text] [PDF]

				T. Enomoto, Y. Noda, A. Mouri, E.-J. Shin, D. Wang, R. Murai, K. Hotta, H. Furukawa, A. Nitta, H.-C. Kim, et al. Long-Lasting Impairment of Associative Learning Is Correlated with a Dysfunction of N-Methyl-D-aspartate-Extracellular Signaling-Regulated Kinase Signaling in Mice after Withdrawal from Repeated Administration of Phencyclidine Mol. Pharmacol., December 1, 2005; 68(6): 1765 - 1774. [Abstract] [Full Text] [PDF]

				A. Kudoh Perioperative Management for Chronic Schizophrenic Patients Anesth. Analg., December 1, 2005; 101(6): 1867 - 1872. [Abstract] [Full Text] [PDF]

				C. R. Yang and L. Chen Targeting Prefrontal Cortical Dopamine D1 and N-Methyl-D-Aspartate Receptor Interactions in Schizophrenia Treatment Neuroscientist, October 1, 2005; 11(5): 452 - 470. [Abstract] [PDF]

				P. D. Butler, V. Zemon, I. Schechter, A. M. Saperstein, M. J. Hoptman, K. O. Lim, N. Revheim, G. Silipo, and D. C. Javitt Early-Stage Visual Processing and Cortical Amplification Deficits in Schizophrenia Arch Gen Psychiatry, May 1, 2005; 62(5): 495 - 504. [Abstract] [Full Text] [PDF]

				E. Jodo, Y. Suzuki, T. Katayama, K.-Y. Hoshino, S. Takeuchi, S.-I. Niwa, and Y. Kayama Activation of Medial Prefrontal Cortex by Phencyclidine is Mediated via a Hippocampo-prefrontal Pathway Cereb Cortex, May 1, 2005; 15(5): 663 - 669. [Abstract] [Full Text] [PDF]

				T. A. Blanpied, R. J. Clarke, and J. W. Johnson Amantadine Inhibits NMDA Receptors by Accelerating Channel Closure during Channel Block J. Neurosci., March 30, 2005; 25(13): 3312 - 3322. [Abstract] [Full Text] [PDF]

				P. Svenningsson, G. G. Nomikos, and P. Greengard Response to Comment on "Diverse Psychotomimetics Act Through a Common Signaling Pathway" Science, July 9, 2004; 305(5681): 180d - 180d. [Full Text] [PDF]

				T.-U. W. Woo, J. P. Walsh, and F. M. Benes Density of Glutamic Acid Decarboxylase 67 Messenger RNA-Containing Neurons That Express the N-Methyl-D-Aspartate Receptor Subunit NR2A in the Anterior Cingulate Cortex in Schizophrenia and Bipolar Disorder Arch Gen Psychiatry, July 1, 2004; 61(7): 649 - 657. [Abstract] [Full Text] [PDF]

				M. E. Jackson, H. Homayoun, and B. Moghaddam NMDA receptor hypofunction produces concomitant firing rate potentiation and burst activity reduction in the prefrontal cortex PNAS, June 1, 2004; 101(22): 8467 - 8472. [Abstract] [Full Text] [PDF]

				M. Martina, Y. Gorfinkel, S. Halman, J. A. Lowe, P. Periyalwar, C. J. Schmidt, and R. Bergeron Glycine transporter type 1 blockade changes NMDA receptor-mediated responses and LTP in hippocampal CA1 pyramidal cells by altering extracellular glycine levels J. Physiol., June 1, 2004; 557(2): 489 - 500. [Abstract] [Full Text] [PDF]

				G. Chen, P. Greengard, and Z. Yan Potentiation of NMDA receptor currents by dopamine D1 receptors in prefrontal cortex PNAS, February 24, 2004; 101(8): 2596 - 2600. [Abstract] [Full Text] [PDF]

				E. S. Emamian, M. Karayiorgou, and J. A. Gogos Decreased Phosphorylation of NMDA Receptor Type 1 at Serine 897 in Brains of Patients with Schizophrenia J. Neurosci., February 18, 2004; 24(7): 1561 - 1564. [Abstract] [Full Text] [PDF]

				J. P. Tyszkiewicz, Z. Gu, X. Wang, X. Cai, and Z. Yan Group II metabotropic glutamate receptors enhance NMDA receptor currents via a protein kinase C-dependent mechanism in pyramidal neurones of rat prefrontal cortex J. Physiol., February 1, 2004; 554(3): 765 - 777. [Abstract] [Full Text] [PDF]

				S. M. Weiss, E. Whawell, R. Upton, and C. T. Dourish Potential for antipsychotic and psychotomimetic effects of A2A receptor modulation Neurology, December 9, 2003; 61(90116): S88 - 93. [Abstract] [Full Text]

				A. R. WEST, S. B. FLORESCO, A. CHARARA, J. A. ROSENKRANZ, and A. A. GRACE Electrophysiological Interactions between Striatal Glutamatergic and Dopaminergic Systems Ann. N.Y. Acad. Sci., November 1, 2003; 1003(1): 53 - 74. [Abstract] [Full Text] [PDF]

				J. H. MEADOR-WOODRUFF, S. M. CLINTON, M. BENEYTO, and R. E. McCULLUMSMITH Molecular Abnormalities of the Glutamate Synapse in the Thalamus in Schizophrenia Ann. N.Y. Acad. Sci., November 1, 2003; 1003(1): 75 - 93. [Abstract] [Full Text] [PDF]

				B. MOGHADDAM and M. E. JACKSON Glutamatergic Animal Models of Schizophrenia Ann. N.Y. Acad. Sci., November 1, 2003; 1003(1): 131 - 137. [Abstract] [Full Text] [PDF]

				M. LARUELLE, L. S. KEGELES, and A. ABI-DARGHAM Glutamate, Dopamine, and Schizophrenia: From Pathophysiology to Treatment Ann. N.Y. Acad. Sci., November 1, 2003; 1003(1): 138 - 158. [Abstract] [Full Text] [PDF]

				J. T. COYLE, G. TSAI, and D. GOFF Converging Evidence of NMDA Receptor Hypofunction in the Pathophysiology of Schizophrenia Ann. N.Y. Acad. Sci., November 1, 2003; 1003(1): 318 - 327. [Abstract] [Full Text] [PDF]

				K. W. JOHNSON, A. CLEMENS-SMITH, G. NOMIKOS, R. DAVIS, L. PHEBUS, H. SHANNON, P. LOVE, K. PERRY, J. KATNER, F. BYMASTER, et al. In Vivo Characterization of Changes in Glycine Levels Induced by GlyT1 Inhibitors Ann. N.Y. Acad. Sci., November 1, 2003; 1003(1): 412 - 414. [Full Text] [PDF]

				X. Wang, P. Zhong, Z. Gu, and Z. Yan Regulation of NMDA Receptors by Dopamine D4 Signaling in Prefrontal Cortex J. Neurosci., October 29, 2003; 23(30): 9852 - 9861. [Abstract] [Full Text] [PDF]

				A. Abi-Dargham and H. Moore Prefrontal DA Transmission at D1 Receptors and the Pathology of Schizophrenia Neuroscientist, October 1, 2003; 9(5): 404 - 416. [Abstract] [PDF]

				F. I. Tarazi, R. J. Baldessarini, N. S. Kula, and K. Zhang Long-Term Effects of Olanzapine, Risperidone, and Quetiapine on Ionotropic Glutamate Receptor Types: Implications for Antipsychotic Drug Treatment J. Pharmacol. Exp. Ther., September 1, 2003; 306(3): 1145 - 1151. [Abstract] [Full Text] [PDF]

				G. G. Kinney, M. Burno, U. C. Campbell, L. M. Hernandez, D. Rodriguez, L. J. Bristow, and P. J. Conn Metabotropic Glutamate Subtype 5 Receptors Modulate Locomotor Activity and Sensorimotor Gating in Rodents J. Pharmacol. Exp. Ther., July 1, 2003; 306(1): 116 - 123. [Abstract] [Full Text] [PDF]

				K. Hashimoto, T. Fukushima, E. Shimizu, N. Komatsu, H. Watanabe, N. Shinoda, M. Nakazato, C. Kumakiri, S.-i. Okada, H. Hasegawa, et al. Decreased Serum Levels of D-Serine in Patients With Schizophrenia: Evidence in Support of the N-Methyl-D-Aspartate Receptor Hypofunction Hypothesis of Schizophrenia Arch Gen Psychiatry, June 1, 2003; 60(6): 572 - 576. [Abstract] [Full Text] [PDF]